Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

501 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The addition of daunorubicin to imatinib mesylate in combination with cytarabine improves the response rate and the survival of patients with myeloid blast crisis chronic myelogenous leukemia (AFR01 study).
Deau B, Nicolini FE, Guilhot J, Huguet F, Guerci A, Legros L, Pautas C, Berthou C, Guyotat D, Cony-Makhoul P, Gardembas M, Michallet M, Hayette S, Cayuela JM, Weiss IR, Réa D, Castaigne S, Mahon FX, Guilhot F, Rousselot P. Deau B, et al. Among authors: michallet m. Leuk Res. 2011 Jun;35(6):777-82. doi: 10.1016/j.leukres.2010.11.004. Epub 2010 Dec 10. Leuk Res. 2011. PMID: 21145590 Clinical Trial.
Comparison of 200 mg/m(2) melphalan and 8 Gy total body irradiation plus 140 mg/m(2) melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergroupe Francophone du Myélome 9502 randomized trial.
Moreau P, Facon T, Attal M, Hulin C, Michallet M, Maloisel F, Sotto JJ, Guilhot F, Marit G, Doyen C, Jaubert J, Fuzibet JG, François S, Benboubker L, Monconduit M, Voillat L, Macro M, Berthou C, Dorvaux V, Pignon B, Rio B, Matthes T, Casassus P, Caillot D, Najman N, Grosbois B, Bataille R, Harousseau JL; Intergroupe Francophone du Myélome. Moreau P, et al. Among authors: michallet m. Blood. 2002 Feb 1;99(3):731-5. doi: 10.1182/blood.v99.3.731. Blood. 2002. PMID: 11806971 Free article. Clinical Trial.
Imatinib in combination with cytarabine for the treatment of Philadelphia-positive chronic myelogenous leukemia chronic-phase patients: rationale and design of phase I/II trials.
Guilhot F, Gardembas M, Rousselot P, Tulliez M, Vigier M, Buzyn A, Rigal-Huguet F, Legros L, Michallet M, Berthou C, Najman A, Maloisel F, Mahon FX, Facon T, Berthaud P, Guilhot J; CML French Group. Guilhot F, et al. Among authors: michallet m. Semin Hematol. 2003 Apr;40(2 Suppl 2):92-7. doi: 10.1053/shem.2003.50048. Semin Hematol. 2003. PMID: 12783382 Review.
Results of a prospective phase 2 study combining imatinib mesylate and cytarabine for the treatment of Philadelphia-positive patients with chronic myelogenous leukemia in chronic phase.
Gardembas M, Rousselot P, Tulliez M, Vigier M, Buzyn A, Rigal-Huguet F, Legros L, Michallet M, Berthou C, Cheron N, Maloisel F, Mahon FX, Facon T, Berthaud P, Guilhot J, Guilhot F; CML French Group. Gardembas M, et al. Among authors: michallet m. Blood. 2003 Dec 15;102(13):4298-305. doi: 10.1182/blood-2003-04-1010. Epub 2003 Aug 21. Blood. 2003. PMID: 12933584 Free article. Clinical Trial.
Tandem autologous stem cell transplantation in high-risk de novo multiple myeloma: final results of the prospective and randomized IFM 99-04 protocol.
Moreau P, Hullin C, Garban F, Yakoub-Agha I, Benboubker L, Attal M, Marit G, Fuzibet JG, Doyen C, Voillat L, Berthou C, Ketterer N, Casassus P, Monconduit M, Michallet M, Najman A, Sotto JJ, Bataille R, Harousseau JL; Intergroupe Francophone du Myélome group. Moreau P, et al. Among authors: michallet m. Blood. 2006 Jan 1;107(1):397-403. doi: 10.1182/blood-2005-06-2573. Epub 2005 Sep 6. Blood. 2006. PMID: 16144800 Free article. Clinical Trial.
Prospective comparison of autologous stem cell transplantation followed by dose-reduced allograft (IFM99-03 trial) with tandem autologous stem cell transplantation (IFM99-04 trial) in high-risk de novo multiple myeloma.
Garban F, Attal M, Michallet M, Hulin C, Bourhis JH, Yakoub-Agha I, Lamy T, Marit G, Maloisel F, Berthou C, Dib M, Caillot D, Deprijck B, Ketterer N, Harousseau JL, Sotto JJ, Moreau P. Garban F, et al. Among authors: michallet m. Blood. 2006 May 1;107(9):3474-80. doi: 10.1182/blood-2005-09-3869. Epub 2006 Jan 5. Blood. 2006. PMID: 16397129 Free article. Clinical Trial.
Postremission treatment of elderly patients with acute myeloid leukemia in first complete remission after intensive induction chemotherapy: results of the multicenter randomized Acute Leukemia French Association (ALFA) 9803 trial.
Gardin C, Turlure P, Fagot T, Thomas X, Terre C, Contentin N, Raffoux E, de Botton S, Pautas C, Reman O, Bourhis JH, Fenaux P, Castaigne S, Michallet M, Preudhomme C, de Revel T, Bordessoule D, Dombret H. Gardin C, et al. Among authors: michallet m. Blood. 2007 Jun 15;109(12):5129-35. doi: 10.1182/blood-2007-02-069666. Epub 2007 Mar 6. Blood. 2007. PMID: 17341661 Free article. Clinical Trial.
Clinical outcome of 27 imatinib mesylate-resistant chronic myelogenous leukemia patients harboring a T315I BCR-ABL mutation.
Nicolini FE, Hayette S, Corm S, Bachy E, Bories D, Tulliez M, Guilhot F, Legros L, Maloisel F, Kiladjian JJ, Mahon FX, Lê QH, Michallet M, Roche-Lestienne C, Preudhomme C. Nicolini FE, et al. Among authors: michallet m. Haematologica. 2007 Sep;92(9):1238-41. doi: 10.3324/haematol.11369. Haematologica. 2007. PMID: 17768119 Free article.
501 results